Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Davis AE, Mehrotra S, Friedewald J, Ladner D. Characteristics of a simulation model of the national kidney transplantation system. Poster presented at the 2013 Winter Simulation Conference: Simulation: Making Decisions in a Complex World; December 2013. [abstract] Ieee/Acm Trans Comput Biol Bioinform. 2013 Dec; p.2320-9.
Patel RI, Davis PJ, Orr RJ, Ferrari LR, Rimar S, Hannallah RS, Cohen IT, Colingo K, Donlon JV, Haberkern CM, McGowan FX, Prillaman BA, Parasuraman TV, Creed MR. Single-dose ondansetron prevents postoperative vomiting in pediatric outpatients. Anesth Analg. 1997 Sep;85(3):538-45. doi: 10.1097/00000539-199709000-00011
Gratz I, Allen E, Afshar M, Joslyn AF, Buxbaum J, Prillaman B. The effects of the menstrual cycle on the incidence of postoperative nausea and vomiting (PONV) and efficacy of ondansetron. Anesth Analg. 1996 Sep;83(3):565-9. doi: 10.1097/00000539-199609000-00022